Dinesh Sangarran Ramachandram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dinesh Sangarran Ramachandram has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Chia Siang Kow
IMU University
52 shared publications - Syed Shahzad Hasan
Department of Pharmacy, School of Applied Sciences University of Huddersfield Huddersfield UK
41 shared publications - Kaeshaelya Thiruchelvam
School of Pharmacy, IMU University Kuala Lumpur Malaysia
29 shared publications Syed Shahzad Hasan
School of Applied Sciences University of Huddersfield Queensgate Huddersfield UK
5 shared publications- Abdullah Faiz Zaihan
Department of Pharmacy Shah Alam Hospital Shah Alam Selangor Malaysia
4 shared publications Chia Siang Kow
School of Pharmacy, IMU University Kuala Lumpur Malaysia
4 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (5) , e70325
Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis
Background: Semaglutide and tirzepatide produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain. Objective: To estimate post‐discontinuation weight‐regain trajectories and explore predictors of faster regain. Methods: We used published timepoint‐level aggregate data from studies evaluating weight change after discontinuation of semaglutide or tirzepatide to perform a Bayesian hierarchical longitudinal re‐analysis. The model estimated weight loss at cessation, monthly regain rate, time to 50% regain, and time to return to baseline weight. Bayesian meta‐regression examined medication type, magnitude of initial weight loss, and post‐discontinuation behavioural or lifestyle support. Longer‐term estimates assumed a constant linear regain rate. Results: Six studies comprising 10 intervention arms and 1776 participants were included, with observed follow‐up ranging from 4 to 52 weeks. Estimated weight loss at cessation was 15.35 kg (95% credible interval [CrI] 11.18–19.60), followed by regain of 1.04 kg/month (95% CrI 0.80–1.29). Based on the linear model, 50% of initial weight loss was projected to be regained by 7.50 months (95% CrI 5.05–10.57), with return to baseline weight by 15.00 months (95% CrI 10.10–21.13). Tirzepatide showed numerically faster regain than semaglutide in unadjusted analyses, but no clear independent drug‐specific difference was evident after adjustment. Greater initial weight loss showed the strongest directional association with faster regain, although the credible interval included zero. Behavioural or lifestyle support was directionally associated with slower regain, but the estimate was imprecise. Conclusions: Weight regain after discontinuation of semaglutide or tirzepatide was rapid and clinically meaningful. Because estimates beyond 52 weeks were model‐based extrapolations, they should be interpreted cautiously. Early monitoring and proactive maintenance planning may be warranted after treatment cessation.
- 31 August 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (5) , e70325
Open AccessWeight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis
Background: Semaglutide and tirzepatide produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain. Objective: To estimate post‐discontinuation weight‐regain trajectories and explore predictors of faster regain. Methods: We used published timepoint‐level aggregate data from studies evaluating weight change after discontinuation of semaglutide or tirzepatide to perform a Bayesian hierarchical longitudinal re‐analysis. The model estimated weight loss at cessation, monthly regain rate, time to 50% regain, and time to return to baseline weight. Bayesian meta‐regression examined medication type, magnitude of initial weight loss, and post‐discontinuation behavioural or lifestyle support. Longer‐term estimates assumed a constant linear regain rate. Results: Six studies comprising 10 intervention arms and 1776 participants were included, with observed follow‐up ranging from 4 to 52 weeks. Estimated weight loss at cessation was 15.35 kg (95% credible interval [CrI] 11.18–19.60), followed by regain of 1.04 kg/month (95% CrI 0.80–1.29). Based on the linear model, 50% of initial weight loss was projected to be regained by 7.50 months (95% CrI 5.05–10.57), with return to baseline weight by 15.00 months (95% CrI 10.10–21.13). Tirzepatide showed numerically faster regain than semaglutide in unadjusted analyses, but no clear independent drug‐specific difference was evident after adjustment. Greater initial weight loss showed the strongest directional association with faster regain, although the credible interval included zero. Behavioural or lifestyle support was directionally associated with slower regain, but the estimate was imprecise. Conclusions: Weight regain after discontinuation of semaglutide or tirzepatide was rapid and clinically meaningful. Because estimates beyond 52 weeks were model‐based extrapolations, they should be interpreted cautiously. Early monitoring and proactive maintenance planning may be warranted after treatment cessation.
- 21 July 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (8) , 5835-5842
The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials
Background Knee osteoarthritis (OA) is a prevalent chronic condition characterized by joint pain and functional impairment. While non-steroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of pharmacologic management, a subset of patients may experience persistent symptoms due to central sensitization. Pregabalin, a neuromodulator used in neuropathic pain, has been proposed as an adjunctive treatment for OA, but its efficacy remains unclear. Objective To evaluate the effectiveness and safety of pregabalin in reducing pain and improving function among patients with knee OA through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods We searched PubMed, Embase, Scopus, and Cochrane CENTRAL from inception to June 2025 for RCTs comparing pregabalin (alone or in combination with NSAIDs) versus control (NSAIDs or placebo) in knee OA patients. Primary outcomes were pain (Visual Analog Scale, VAS) and function (Western Ontario and McMaster Universities Osteoarthritis Index, WOMAC). A random-effects model was used to calculate pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane RoB 2.0 tool. Results Three RCTs comprising four treatment arms with 214 patients were included. Pregabalin, when combined with NSAIDs, resulted in significant functional improvement (WMD: − 10.55; 95% CI: − 19.47 to − 1.63) and a non-significant trend toward pain reduction (WMD: − 0.63; 95% CI: − 1.44 to 0.18). Pregabalin monotherapy was less effective than combination therapy. Moderate to high heterogeneity was observed. Adverse events, primarily dizziness and somnolence, were mild and did not lead to discontinuation. Conclusion Pregabalin may enhance functional outcomes and contribute to pain relief when used as adjunctive therapy with NSAIDs in knee OA patients. Its benefit as monotherapy remains limited. While pregabalin was generally well-tolerated, larger, high-quality trials with longer follow-up are needed to confirm its role and long-term safety.
- 21 July 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (8) , 5835-5842
The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials
Background Knee osteoarthritis (OA) is a prevalent chronic condition characterized by joint pain and functional impairment. While non-steroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of pharmacologic management, a subset of patients may experience persistent symptoms due to central sensitization. Pregabalin, a neuromodulator used in neuropathic pain, has been proposed as an adjunctive treatment for OA, but its efficacy remains unclear. Objective To evaluate the effectiveness and safety of pregabalin in reducing pain and improving function among patients with knee OA through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods We searched PubMed, Embase, Scopus, and Cochrane CENTRAL from inception to June 2025 for RCTs comparing pregabalin (alone or in combination with NSAIDs) versus control (NSAIDs or placebo) in knee OA patients. Primary outcomes were pain (Visual Analog Scale, VAS) and function (Western Ontario and McMaster Universities Osteoarthritis Index, WOMAC). A random-effects model was used to calculate pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane RoB 2.0 tool. Results Three RCTs comprising four treatment arms with 214 patients were included. Pregabalin, when combined with NSAIDs, resulted in significant functional improvement (WMD: − 10.55; 95% CI: − 19.47 to − 1.63) and a non-significant trend toward pain reduction (WMD: − 0.63; 95% CI: − 1.44 to 0.18). Pregabalin monotherapy was less effective than combination therapy. Moderate to high heterogeneity was observed. Adverse events, primarily dizziness and somnolence, were mild and did not lead to discontinuation. Conclusion Pregabalin may enhance functional outcomes and contribute to pain relief when used as adjunctive therapy with NSAIDs in knee OA patients. Its benefit as monotherapy remains limited. While pregabalin was generally well-tolerated, larger, high-quality trials with longer follow-up are needed to confirm its role and long-term safety.
- 9 July 2026
- Published by Springer Nature
- p. 3948-3965
Pharmacokinetics
- 19 January 2026
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (4) , 403-409
Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: The optimal timing of initiating direct oral anticoagulants (DOACs) after ischemic stroke in patients with atrial fibrillation (AF) remains uncertain. Early initiation may reduce recurrent stroke risk but raise concerns about hemorrhagic complications. This study aimed to evaluate the efficacy and safety of early versus later anticoagulation after ischemic stroke in AF. Methods: We systematically searched PubMed, EMBASE, CENTRAL, and Scopus from inception to May 22, 2025, for randomized controlled trials (RCTs) comparing early (≤4 days) versus later (5-14 days) DOAC initiation post-stroke in AF. Primary outcomes were recurrent ischemic stroke, symptomatic intracerebral hemorrhage (sICH), and all-cause mortality. Data were pooled using MetaXL (version 5.3) with a random-effects model. Heterogeneity was assessed using the Chi-square test and I 2 statistic. Results: Five RCTs (n = 6810) were included. Early anticoagulation showed a non-significant reduction in recurrent ischemic stroke (OR 0.80, 95% CI: 0.59-1.09; I 2 = 1%) and no significant difference in sICH (OR 0.92, 95% CI: 0.45-1.85; I 2 = 0%) or all-cause mortality (OR 0.94, 95% CI: 0.78-1.14; I 2 = 0%). Across all outcomes, heterogeneity was low and findings were consistent. Conclusion: Early initiation of DOACs after ischemic stroke in AF appears safe and may modestly reduce stroke recurrence without increasing hemorrhagic or mortality risk. These findings support individualized decision-making and suggest that early anticoagulation is a reasonable strategy in appropriately selected patients.
- 19 January 2026
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (4) , 403-409
Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: The optimal timing of initiating direct oral anticoagulants (DOACs) after ischemic stroke in patients with atrial fibrillation (AF) remains uncertain. Early initiation may reduce recurrent stroke risk but raise concerns about hemorrhagic complications. This study aimed to evaluate the efficacy and safety of early versus later anticoagulation after ischemic stroke in AF. Methods: We systematically searched PubMed, EMBASE, CENTRAL, and Scopus from inception to May 22, 2025, for randomized controlled trials (RCTs) comparing early (≤4 days) versus later (5-14 days) DOAC initiation post-stroke in AF. Primary outcomes were recurrent ischemic stroke, symptomatic intracerebral hemorrhage (sICH), and all-cause mortality. Data were pooled using MetaXL (version 5.3) with a random-effects model. Heterogeneity was assessed using the Chi-square test and I 2 statistic. Results: Five RCTs (n = 6810) were included. Early anticoagulation showed a non-significant reduction in recurrent ischemic stroke (OR 0.80, 95% CI: 0.59-1.09; I 2 = 1%) and no significant difference in sICH (OR 0.92, 95% CI: 0.45-1.85; I 2 = 0%) or all-cause mortality (OR 0.94, 95% CI: 0.78-1.14; I 2 = 0%). Across all outcomes, heterogeneity was low and findings were consistent. Conclusion: Early initiation of DOACs after ischemic stroke in AF appears safe and may modestly reduce stroke recurrence without increasing hemorrhagic or mortality risk. These findings support individualized decision-making and suggest that early anticoagulation is a reasonable strategy in appropriately selected patients.
- Open Access
- 1 January 2026
- Published by Wiley in Health & Social Care in the Community
- Vol. 2026 (1) , 4919244
Role of AI and Digital Health Interventions in Medication Management Among People With Dementia: Perspectives Among Pharmacists
Background: Medication management for people living with dementia is often complicated by cognitive decline, polypharmacy and increasing reliance on caregivers. Artificial intelligence (AI) and digital health technologies have emerged as promising approaches to support medication management, yet little is known about pharmacists’ perspectives on their use within the Malaysian healthcare context. Objective: To explore Malaysian pharmacists’ perspectives on medication management for people living with dementia and the potential role of AI and digital health interventions in supporting dementia care. Methods: An exploratory qualitative study was conducted using semistructured interviews with 10 pharmacists from community and hospital settings in Malaysia. Interviews were audio‐recorded, transcribed verbatim and analysed using Braun and Clarke’s thematic analysis. The study was reported in accordance with the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six themes were identified. Pharmacists described significant challenges in dementia medication management, including limited public awareness, caregiver‐related difficulties and barriers to medication adherence. Participants emphasised the importance of person‐centred care, multidisciplinary collaboration and active caregiver involvement in supporting safe and effective medication use. Although pharmacists expressed positive attitudes towards AI and digital health interventions, they consistently viewed these technologies as tools to support, rather than replace, professional judgement. Concerns regarding data privacy, implementation costs, trustworthiness and professional training highlighted the need for responsible implementation within routine clinical practice. Conclusion: Malaysian pharmacists recognise the potential of AI and digital health interventions to strengthen medication management for people living with dementia when implemented responsibly and integrated into routine practice. Future research should evaluate their real‐world implementation, effectiveness and acceptability to support evidence‐based, person‐centred dementia care.
- 1 January 2026
- Published by Wiley in Health & Social Care in the Community
- Vol. 2026 (1) , 4919244
Open AccessRole of AI and Digital Health Interventions in Medication Management Among People With Dementia: Perspectives Among Pharmacists
Background: Medication management for people living with dementia is often complicated by cognitive decline, polypharmacy and increasing reliance on caregivers. Artificial intelligence (AI) and digital health technologies have emerged as promising approaches to support medication management, yet little is known about pharmacists’ perspectives on their use within the Malaysian healthcare context. Objective: To explore Malaysian pharmacists’ perspectives on medication management for people living with dementia and the potential role of AI and digital health interventions in supporting dementia care. Methods: An exploratory qualitative study was conducted using semistructured interviews with 10 pharmacists from community and hospital settings in Malaysia. Interviews were audio‐recorded, transcribed verbatim and analysed using Braun and Clarke’s thematic analysis. The study was reported in accordance with the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six themes were identified. Pharmacists described significant challenges in dementia medication management, including limited public awareness, caregiver‐related difficulties and barriers to medication adherence. Participants emphasised the importance of person‐centred care, multidisciplinary collaboration and active caregiver involvement in supporting safe and effective medication use. Although pharmacists expressed positive attitudes towards AI and digital health interventions, they consistently viewed these technologies as tools to support, rather than replace, professional judgement. Concerns regarding data privacy, implementation costs, trustworthiness and professional training highlighted the need for responsible implementation within routine clinical practice. Conclusion: Malaysian pharmacists recognise the potential of AI and digital health interventions to strengthen medication management for people living with dementia when implemented responsibly and integrated into routine practice. Future research should evaluate their real‐world implementation, effectiveness and acceptability to support evidence‐based, person‐centred dementia care.
- Open Access
- 26 December 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 530-543
The therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials
Background: Major depressive disorder (MDD) is a globally prevalent psychiatric condition associated with significant morbidity and often suboptimal treatment outcomes. Probiotics have emerged as a promising adjunctive therapy targeting the gut–brain axis in MDD. Aims: This systematic review aimed to critically evaluate the efficacy of probiotics in the treatment of clinically diagnosed MDD, assess methodological quality and therapeutic readiness, and identify research gaps relevant to clinical application. Methods: A systematic search of MEDLINE, Web of Science, and PubMed was conducted in June 2023 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Double-blind, placebo-controlled, randomised controlled trials (RCTs) involving adults with MDD were included. Risk of bias was assessed using the Cochrane Risk of Bias tool. Results: Thirteen RCTs involving 437 adults aged 18–75 years with MDD were included. Most trials reported improvements in depressive symptoms, particularly in outpatients with mild-to-moderate MDD treated with multi-strain formulations containing Lactobacillus and Bifidobacterium over 4–8 weeks. Secondary outcomes across metabolic, inflammatory, cognitive, neurotrophic, and gastrointestinal domains showed variable improvements. Probiotic benefits were most consistent in Iranian outpatients, more modest in European inpatients, and positive but variable in East Asian outpatients. Risk of bias was predominantly low, though attrition, selective reporting, and methodological heterogeneity remained sources of bias. Conclusions: Probiotics appear safe and well-tolerated, with modest adjunctive benefit in MDD, most evident for multi-strain formulations in younger, outpatient populations with mild-to-moderate symptoms, supporting an individualised, context-dependent approach. Future trials should stratify patients, extend intervention durations, and integrate mechanistic endpoints to refine patient-tailored recommendations.
- 26 December 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 530-543
Open AccessThe therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials
Background: Major depressive disorder (MDD) is a globally prevalent psychiatric condition associated with significant morbidity and often suboptimal treatment outcomes. Probiotics have emerged as a promising adjunctive therapy targeting the gut–brain axis in MDD. Aims: This systematic review aimed to critically evaluate the efficacy of probiotics in the treatment of clinically diagnosed MDD, assess methodological quality and therapeutic readiness, and identify research gaps relevant to clinical application. Methods: A systematic search of MEDLINE, Web of Science, and PubMed was conducted in June 2023 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Double-blind, placebo-controlled, randomised controlled trials (RCTs) involving adults with MDD were included. Risk of bias was assessed using the Cochrane Risk of Bias tool. Results: Thirteen RCTs involving 437 adults aged 18–75 years with MDD were included. Most trials reported improvements in depressive symptoms, particularly in outpatients with mild-to-moderate MDD treated with multi-strain formulations containing Lactobacillus and Bifidobacterium over 4–8 weeks. Secondary outcomes across metabolic, inflammatory, cognitive, neurotrophic, and gastrointestinal domains showed variable improvements. Probiotic benefits were most consistent in Iranian outpatients, more modest in European inpatients, and positive but variable in East Asian outpatients. Risk of bias was predominantly low, though attrition, selective reporting, and methodological heterogeneity remained sources of bias. Conclusions: Probiotics appear safe and well-tolerated, with modest adjunctive benefit in MDD, most evident for multi-strain formulations in younger, outpatient populations with mild-to-moderate symptoms, supporting an individualised, context-dependent approach. Future trials should stratify patients, extend intervention durations, and integrate mechanistic endpoints to refine patient-tailored recommendations.
- Open Access
Documenting Clinical Outcomes Assessed in Outpatients with COVID-19: A Scoping Review of Randomized Controlled Trials
The COVID-19 pandemic initially focused clinical efforts on hospitalized patients. However, as the pandemic progressed, attention shifted to outpatients who often experience milder symptoms yet still contribute to viral transmission. This scoping review aimed to document and evaluate the clinical outcomes assessed in randomized controlled trials (RCTs) involving outpatients with COVID-19, identifying gaps and areas for improvement in trial design. This review followed the PRISMA-ScR guidelines. A comprehensive search of four electronic databases (PubMed, Scopus, Cochrane CENTRAL, and Web of Science) was conducted for RCTs published between December 2019 and December 2023. Studies were included if they involved outpatients with confirmed COVID-19 and reported clinical outcomes. Data were extracted from eligible studies, and outcomes were categorized using the COMET taxonomy. A total of 91 studies were included, representing a wide geographical distribution, with the USA, Iran, and Brazil contributing the most studies. The most frequently investigated treatments included hydroxychloroquine, fluvoxamine, convalescent plasma, and ivermectin. Key outcomes focused on hospitalization rates, symptom resolution, and disease progression. Mortality, although less common in outpatients, was reported in 65 studies, underscoring the importance of outpatient interventions. This review highlights the need for standardized outcome measures in outpatient COVID-19 trials.
Open AccessDocumenting Clinical Outcomes Assessed in Outpatients with COVID-19: A Scoping Review of Randomized Controlled Trials
The COVID-19 pandemic initially focused clinical efforts on hospitalized patients. However, as the pandemic progressed, attention shifted to outpatients who often experience milder symptoms yet still contribute to viral transmission. This scoping review aimed to document and evaluate the clinical outcomes assessed in randomized controlled trials (RCTs) involving outpatients with COVID-19, identifying gaps and areas for improvement in trial design. This review followed the PRISMA-ScR guidelines. A comprehensive search of four electronic databases (PubMed, Scopus, Cochrane CENTRAL, and Web of Science) was conducted for RCTs published between December 2019 and December 2023. Studies were included if they involved outpatients with confirmed COVID-19 and reported clinical outcomes. Data were extracted from eligible studies, and outcomes were categorized using the COMET taxonomy. A total of 91 studies were included, representing a wide geographical distribution, with the USA, Iran, and Brazil contributing the most studies. The most frequently investigated treatments included hydroxychloroquine, fluvoxamine, convalescent plasma, and ivermectin. Key outcomes focused on hospitalization rates, symptom resolution, and disease progression. Mortality, although less common in outpatients, was reported in 65 studies, underscoring the importance of outpatient interventions. This review highlights the need for standardized outcome measures in outpatient COVID-19 trials.
- Open Access
- 15 October 2025
- Published by Taylor & Francis in Interactive Learning Environments
- Vol. 34 (6) , 1-14
Virtual reality (VR) and augmented reality (AR) in pharmacy education: perspectives among pharmacists in the workforce (a qualitative study)
- 15 October 2025
- Published by Taylor & Francis in Interactive Learning Environments
- Vol. 34 (6) , 1-14
Open AccessVirtual reality (VR) and augmented reality (AR) in pharmacy education: perspectives among pharmacists in the workforce (a qualitative study)